The Neuroprotective Disease-Modifying Potential of Psychotropics in Parkinson's Disease

The Neuroprotective Disease-Modifying Potential of Psychotropics in Parkinson's Disease

Neuroprotective treatments in Parkinson's disease (PD) have remained elusive. Psychotropics are commonly prescribed in PD without regard to their pathobiological effects. The authors investigated the effects of psychotropics on pathobiological proteins, proteasomal activity, mitochondrial funct...

Full description

Saved in:

Bibliographic Details
Main Authors:	Edward C. Lauterbach, Leonardo F. Fontenelle, Antonio L. Teixeira
Format:	Article
Language:	English
Published:	Wiley 2012-01-01
Series:	Parkinson's Disease
Online Access:	http://dx.doi.org/10.1155/2012/753548
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Neuropsychiatry of Parkinson's Disease
by: Antonio L. Teixeira, et al.
Published: (2012-01-01)

Potential Neuroprotective Effect of the Endocannabinoid System on Parkinson’s Disease
by: María Fernanda Urmeneta-Ortíz, et al.
Published: (2024-01-01)

Microglial Ion Channels as Potential Targets for Neuroprotection in Parkinson’s Disease
by: Jason R. Richardson, et al.
Published: (2013-01-01)

Neuroprotective Transcription Factors in Animal Models of Parkinson Disease
by: François-Xavier Blaudin de Thé, et al.
Published: (2016-01-01)

Older Adults with Alzheimer’s Disease, Comorbid Arthritis and Prescription of Psychotropic Medications
by: Judith E Balfour, et al.
Published: (2003-01-01)

Assessing the neuroprotective potential of Eucalyptus globulus essential oil in a 6-hydroxydopamine rat model of Parkinson's disease
by: Aracely Janneth Naranjo-Viteri, et al.
Published: (2025-03-01)

Neuroplasticity and Neuroprotective Effect of Treadmill Training in the Chronic Mouse Model of Parkinson’s Disease
by: Ewelina Palasz, et al.
Published: (2019-01-01)

Enhanced Neuroprotective Effects of Coadministration of Tetrandrine with Glutathione in Preclinical Model of Parkinson’s Disease
by: Xiang-Yun Li, et al.
Published: (2015-01-01)

Weight Gain, Obesity, and Psychotropic Prescribing
by: Nikhil Nihalani, et al.
Published: (2011-01-01)

Anti-Inflammatory and Neuroprotective Role of Natural Product Securinine in Activated Glial Cells: Implications for Parkinson’s Disease
by: Dmitri Leonoudakis, et al.
Published: (2017-01-01)

Therapeutic Role of Protein Tyrosine Phosphatase 1B in Parkinson’s Disease via Antineuroinflammation and Neuroprotection In Vitro and In Vivo
by: Chien-Wei Feng, et al.
Published: (2020-01-01)

Neuroprotective Effect of Intrastriatal Caffeic Acid Phenethyl Ester Treatment in 6-OH Dopamine Model of Parkinson’s Disease in Rats
by: Burak Cem Soner, et al.
Published: (2021-01-01)

Palmitoylethanolamide Is a Disease-Modifying Agent in Peripheral Neuropathy: Pain Relief and Neuroprotection Share a PPAR-Alpha-Mediated Mechanism
by: L. Di Cesare Mannelli, et al.
Published: (2013-01-01)

Long-Term Voluntary Physical Exercise Exerts Neuroprotective Effects and Motor Disturbance Alleviation in a Rat Model of Parkinson’s Disease
by: Wan-Ling Tsai, et al.
Published: (2019-01-01)

Can a Positive Allosteric Modulation of GABAergic Receptors Improve Motor Symptoms in Patients with Parkinson’s Disease? The Potential Role of Zolpidem in the Treatment of Parkinson’s Disease
by: Antonio Daniele, et al.
Published: (2016-01-01)

Meta-Analysis of Visual Evoked Potential and Parkinson’s Disease
by: Song-bin He, et al.
Published: (2018-01-01)

Potential Biomarkers of the Earliest Clinical Stages of Parkinson’s Disease
by: Anelya Kh. Alieva, et al.
Published: (2015-01-01)

Neuroprotective effects of gastrodin in both in vivo and in vitro models of Parkinson's disease: Mechanisms from the perspective of oxidative stress, ferroptosis, and cellular senescence
by: Shanshan Li, et al.
Published: (2025-02-01)

Pentoxifylline Neuroprotective Effects Are Possibly Related to Its Anti-Inflammatory and TNF-Alpha Inhibitory Properties, in the 6-OHDA Model of Parkinson’s Disease
by: Kelly Rose Tavares Neves, et al.
Published: (2015-01-01)

Neuroprotective Effects of Salidroside in the MPTP Mouse Model of Parkinson’s Disease: Involvement of the PI3K/Akt/GSK3β Pathway
by: Wei Zhang, et al.
Published: (2016-01-01)

Event-Related Potentials in Parkinson’s Disease Patients with Visual Hallucination
by: Yang-Pei Chang, et al.
Published: (2016-01-01)

Decisions about the use of psychotropic medication during pregnancy: a qualitative study
by: Irene Petersen, et al.
Published: (2016-01-01)

Correction: Impact of the COVID-19 pandemic on psychotropic prescribing: a systematic review
Published: (2025-01-01)

Mitochondrial Dysfunction in Parkinson's Disease
by: P. C. Keane, et al.
Published: (2011-01-01)

Neuroprotection and Functional Recovery Associated with Decreased Microglial Activation Following Selective Activation of mGluR2/3 Receptors in a Rodent Model of Parkinson's Disease
by: Hugh Chan, et al.
Published: (2010-01-01)

Neuroprotective role of epigallocatechin-3-gallate, albeginin and melanoxetin in alzheimer's disease
by: Arif Malik, et al.
Published: (2025-02-01)

Event-Related Potentials Elicited by Face and Face Pareidolia in Parkinson’s Disease
by: Gulsum Akdeniz, et al.
Published: (2020-01-01)

Therapeutic Potential of α-Synuclein Evolvability for Autosomal Recessive Parkinson’s Disease
by: Jianshe Wei, et al.
Published: (2021-01-01)

Rehabilitation and Parkinson’s Disease
by: Gammon M. Earhart, et al.
Published: (2012-01-01)

Camptocormia in Parkinson's Disease
by: Kazuo Abe, et al.
Published: (2010-01-01)

Forensic Characteristics of Crimes in the Field of Trafficking in Narcotic Drugs, Psychotropic Substances, Their Analogues or Precursors
by: D. V. Golovin
Published: (2021-09-01)

SPECT Findings in Alzheimer’s Disease and Parkinson’s Disease with Dementia
by: S. E. Starkstein, et al.
Published: (1997-01-01)

The Role of the Gastrointestinal Microbiota in Parkinson’s Disease
by: Maurizio Gabrielli, et al.
Published: (2024-12-01)

Recurrent Falls in People with Parkinson’s Disease without Cognitive Impairment: Focusing on Modifiable Risk Factors
by: Lorena R. S. Almeida, et al.
Published: (2014-01-01)

Joint effect of modifiable risk factors on Parkinson’s disease: a large-scale longitudinal study
by: Panlong Li, et al.
Published: (2025-01-01)

Orthostatic Hypotension in Patients with Parkinson’s Disease and Atypical Parkinsonism
by: Seyed-Mohammad Fereshtehnejad, et al.
Published: (2014-01-01)

Genetic Rat Models of Parkinson's Disease
by: Ryan M. Welchko, et al.
Published: (2012-01-01)

Synthesis of Surfactants Derived from 2-Mercaptobenzimidazole and Study of Their Acute Toxicity and Analgesic and Psychotropic Activities
by: Terence Nguema Ongone, et al.
Published: (2019-01-01)

Potential Therapeutic Drugs for Parkinson’s Disease Based on Data Mining and Bioinformatics Analysis
by: Chuan Xu, et al.
Published: (2018-01-01)

Exploring the Potential Imaging Biomarkers for Parkinson’s Disease Using Machine Learning Approach
by: Illia Mushta, et al.
Published: (2024-12-01)